Development of an experimental hemolytic uremic syndrome in rats
- 177 Downloads
Escherichia coli strains producing Shiga toxins (Stxs) colonize the lower gastrointestinal tract and cause watery diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome (HUS). HUS is characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. Oliguria associated with acute tubular necrosis and microangiopathic thrombosis has been reported as the most common cause of renal failure in Argentinean children. Our study was undertaken to obtain a model of HUS in rats that was similar to the clinical and renal histopathology findings described in humans. Rats were intraperitoneally inoculated with culture supernatant from recombinant E. coli expressing Stx2. Glomerular filtrate volume evaluated from clearance of creatinine resulted in a progressive reduction (from 53% at 24 h to 90% at 48 h). Urine volume increased significantly at 24 h but returned to normal levels at 48 h. Evidence of thrombocytopenia, anemia and leukocytosis was documented. Macroscopic analysis revealed a hyperemic peritoneal face with intestinal water accumulation. The kidneys were friable and congestive. Histopathological analysis showed glomerular and tubular necrosis as well as microangiopathic thrombosis. Our findings indicated vascular damage and kidney lesions similar to those described in humans with HUS.
KeywordsHemolytic uremic syndrome Acute tubular necrosis Thrombotic microangiopathy Shiga toxin Diarrhea
This paper was presented at the 50th Annual Scientific Meeting, Argentine Society of Clinical Investigation (SAIC), Mar del Plata, Argentina, 29th November to 2nd December, 2005, and the 6th International Symposium on Shiga toxin (Verocytotoxin-producing Escherichia coli infection, Melbourne, Australia, 29th October to 1st November, 2006. This work was supported by the University of Buenos Aires (M038, M827), the National Council of Research (CONICET, PIP 5587) and ANPCYT (PICT-26224). The authors gratefully acknowledge Claudio Mirabelli for his excellent technical assistance.
- 7.Scully RE, Mark EJ, McNeely WF, Ebeling SH, Phillips LD (1995) Case records of the Massachusetts General Hospital. N Engl J Med 336:1587–1594Google Scholar
- 10.Rivas M, Balbi L, Miliwebsky ES, Garcia B, Tous MI, Leardini NA, Prieto MA, Chillemi GM, De Principi ME (1998) Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga-toxin producing Escherichia coli infection. Medicina (B. Aires) 58:1–7Google Scholar
- 12.Rivas M, Milwebsky E, Chinen I, Deza N, Leotta G (2006) The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission. Medicina (B. Aires) 66:27–32Google Scholar
- 13.Exeni R (2001) Síndrome Urémico Hemolítico. Arch Latin Nefr Ped 1:35–56Google Scholar
- 35.Kato G, McGowan V, Machado R, Little J, Taylor J VI, Morris C, Nichols J, Wang X, Poljakovic M, Morris Jr S, Gladwin M (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107:2279–2285CrossRefGoogle Scholar
- 37.Donato H, Rendo P, Exeni R, Rapetti MC, Antonuccio M, Galvagni A, Grimoldi I, Exeni A (1997) Erythropoietin deficiency in children with acute renal insufficiency due to hemolytic uremic syndrome. Hematología (B. Aires) 1:5–11Google Scholar